Expediting Drug Development in Japan: Key PMDA Initiatives

ELIQUENT Japan > MRCT

2025.08.26

Medical,balancing,act.,a,group,of,medicine,pills,and,antibiotics

Expediting Drug Development in Japan: Key PMDA Initiatives

IntroductionPMDA has reduced median new drug review times from over 600 days in 2005 to 333 days in 2023, matc […]

COMPANY

Company Name: Eliquent Japan, Inc.
Location: Shinjuku i-Land Tower 41F, 6-5-1 Nishi Shinjuku, Shinjuku-ku 163-1341 Tokyo, Japan
Representative Director, CEO: Shunsuke Iwano
Business Scope: Regulatory Consulting
 Phone:+81-3-6304-5570